Inder M Verma

6500940, Dec 31, 2002

Jun 9, 1999

09/328714

Inder M. Verma - La Jolla CA
Mark Schmitt - La Jolla CA
Nikunj V. Somia - La Jolla CA

The Salk Institute for Biological Studies - La Jolla CA

C07H 2104

536 235, 536 241, 530350, 4353201, 435325, 4352523, 435235

A substantially purified lifeguard (LFG) polypeptide is provided. The polypeptide includes an amino acid sequence as set forth in SEQ ID NO:2, or a conservative variant thereof. An isolated polynucleotide is provided that encodes an amino acid sequence as set forth in SEQ ID NO:2, or a conservative variant thereof. An antibody is provided that binds to a polypeptide having an amino acid sequence as set forth in SEQ ID NO:2. A method is provided for identifying a compound which affects a function a polypeptide as set forth in SEQ ID NO:2, or a conservative variant thereof, or affects the expression of a polynucleotide comprising a sequence as set forth in SEQ ID NO:1. A method is provided for treating a subject with a disorder associated with decreased or increased Fas-mediated cell death. A method is provided for treating a patient having or at risk of having a disorder associated with increased Fas-mediated cell death.

6645942, Nov 11, 2003

Apr 22, 1994

08/232452

Inder Mohan Verma - Solana Beach CA
Daniel Claude St. Louis - Gaithersburg MD

The Salk Institute for Biological Studies - La Jolla CA

A61K 3170

514 44, 435325, 424 9321, 424572

The present invention is a somatic cell gene therapy method that is especially useful for the treatment of certain diseases that are caused by gene defects. According to the invention, fibroblast cells are transduced so that they express a âreplacementâ gene of interest. These transduced fibroblasts are preferably fixed in vitro in an extracellular matrix, and then implanted in the loose connective tissue of the skin of an individual or animal to be treated. Because the fibroblasts are implanted in a highly vascularized compartment of the skin i. e. , loose connective tissue of the dermis, the transduced cells, and thus their âreplacementâ gene products, have direct access to the circulatory system. As a result the needed replacement gene products can easily and efficiently be distributed to other parts of the body. When the gene therapy is no longer needed, the implanted fibroblasts can be conveniently removed.

7090837, Aug 15, 2006

Jan 16, 2004

10/760123

Brian Spencer - San Diego CA, US
Robert Marr - San Diego CA, US
Inder M. Verma - La Jolla CA, US

The Salk Institute for Biological Studies - La Jolla CA

A61K 48/00
C12N 5/00
C12N 5/15
C12N 15/63
C12P 21/06

424 932, 435 691, 4353201, 435325, 435455, 424 931

This disclosure provides lentiviral vectors containing an attachment incompetent fusogenic polypeptide and a heterologous targeting polypeptide. Also provided are lentiviral packaging constructs, lentiviral packaging systems, and lentiviral gene delivery systems. Finally, methods of transducing a cell and methods of targeting a gene to a cell or tissue using the disclosed lentiviral vectors and systems are also provided.

8598840, Dec 3, 2013

Apr 14, 2011

13/086927

Larry James Yount - Scottsdale AZ, US
Willard Ahart Blevins - Glendale AZ, US
Inder Jit Verma - Phoenix AZ, US

LaunchPoint Energy and Power LLC - Scottsdale AZ

H02J 7/00

320107, 320134, 320136

A fault tolerant battery management system includes redundancy, with applications including electric vehicles. Portions of its circuitry are constituted in distinct fault domains with control, monitoring, and balancing of cells circuitry fault-effect-isolated from the circuitry associated with built-in real-time testing. Built-in tests are orchestrated in fault domains isolated from the functional circuitry being verified. These built-in tests provide test stimulus unique for each cell measurement. Cell balancing is performed in a fault tolerant manner. It takes at least two independent faults, in two mutually distinct fault domains, to negatively affect balancing capability or to interfere with a redundant circuit's ability to operate. The built-in tests allow operation without the requirement for data cross-compare between redundant measuring electronic elements. Testing and balancing functions are interlocked through encoded enabling methodologies and transmit enables on serial buses.

20010009772, Jul 26, 2001

Mar 12, 2001

09/803863

Inder Verma - Solana Beach CA, US
Tal Kafri - San Diego CA, US
Frederic Bushman - Encinitas CA, US
Mark Hansen - San Diego CA, US

C12N007/01
C12N005/08
A61K031/70
C12P021/06
C07K001/00

435/325000, 435/369000, 435/235100, 530/350000, 435/366000, 435/069100, 435/069300, 435/440000, 435/456000, 435/455000, 435/457000, 435/458000, 435/236000, 435/320100, 514/044000, 536/023720

The present invention provides packaging cell lines and recombinant lentiviral or retroviral particles produced therefrom, particularly pseudotyped retroviral particles. The packaging cell lines of the invention are produced by inducibly expressing an envelope protein by methods described herein. Also described is a screening assay for compounds that affect integration of viral nucleic acid into target (e.g., host) nucleic acid. Such compounds are identified based on their effect on viral integrase.

20030158142, Aug 21, 2003

Dec 20, 2002

10/327697

Inder Verma - La Jolla CA, US
Mark Schmitt - La Jolla CA, US
Nikunj Somia - La Jolla CA, US

A61K048/00
A01K067/027
A61K039/395
C07K016/30

514/044000, 530/388800, 424/155100, 800/018000

A substantially purified lifeguard (LFG) polypeptide is provided. The polypeptide includes an amino acid sequence as set forth in SEQ ID NO: 2, or a conservative variant thereof. An isolated polynucleotide is provided that encodes an amino acid sequence as set forth in SEQ ID NO: 2, or a conservative variant thereof. An antibody is provided that binds to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 2. A method is provided for identifying a compound which affects a function of a polypeptide as set forth in SEQ ID NO: 2, or a conservative variant thereof, or affects the expression of a polynucleotide comprising a sequence as set forth in SEQ ID NO: 1. A method is provided for treating a subject with a disorder associated with decreased or increased Fas-mediated cell death. A method is provided for treating a patient having or at risk of having a disorder associated with increased Fas-mediated cell death.

20040234504, Nov 25, 2004

Dec 18, 2003

10/742740

Inder Verma - La Jolla CA, US
Gustavo Tiscornia - San Diego CA, US
Oded Singer - San Diego CA, US

A61K048/00
C12N015/867

424/093200, 435/456000

The invention provides a lentiviral vector capable of inhibiting the expression of at least one target gene. A lentiviral vector of the invention encompasses a first nucleic acid sequence derived from a target gene transcript and a second nucleic acid sequence corresponding to the reverse complement of said first nucleic acid sequence. A lentiviral vector of the invention capable of inhibiting the expression of a target gene is useful in therapeutic applications to inactivate disease-associated transcripts and thereby reduce the severity of inherited metabolic, infectious or malignant conditions. Methods for inhibiting one or more target genes in a cell as well as methods for producing a non-human mammal in which the expression of one or more target genes is inhibited also are provided by the present invention.

20040235169, Nov 25, 2004

Jun 24, 2004

10/475541

Ronald Evans - La Jolla CA, US
Enrique Saez - San Diego CA, US
Inder Verma - La Jolla CA, US
Francesco Galimi - San Diego CA, US

C12N015/85

435/455000, 435/320100

The present invention provides inducible gene transfer systems and gene transfer vectors for the safe and effective transfer and expression of genes in mammalian cells, and for a very high level of control of expression of the transferred genes. The inducible gene transfer systems of the present invention may be lentiviral vectors comprising a self-inactivating 5′ LTR, a modulator-responsive promoter, a nuclear import signal, a promoter operatively associated with a nucleic acid encoding a modulator-responsive receptor, an RNA stabilizing element, and a self-inactivating 3′ LTR. Thus, the present invention provides vectors for packaging and delivering DNA to both dividing and non-dividing cells. The present invention also provides methods for treating subjects with the gene transfer systems of the present invention, and cells containing the gene transfer systems.